Silence Therapeutics Plc Stock Price Prediction

SLN Stock  USD 4.48  0.16  3.70%   
As of today, the RSI of Silence Therapeutics' share price is approaching 43. This usually implies that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Silence Therapeutics, making its price go up or down.

Momentum 43

 Sell Extended

 
Oversold
 
Overbought
The successful prediction of Silence Therapeutics' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Silence Therapeutics PLC, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Silence Therapeutics' stock price prediction:
EPS Estimate Next Quarter
(0.18)
EPS Estimate Current Year
(0.85)
EPS Estimate Next Year
(0.87)
Wall Street Target Price
46.8829
EPS Estimate Current Quarter
(0.13)
Using Silence Therapeutics hype-based prediction, you can estimate the value of Silence Therapeutics PLC from the perspective of Silence Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Silence Therapeutics using Silence Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Silence using crowd psychology based on the activity and movement of Silence Therapeutics' stock price.

Silence Therapeutics Implied Volatility

    
  3.68  
Silence Therapeutics' implied volatility exposes the market's sentiment of Silence Therapeutics PLC stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Silence Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Silence Therapeutics stock will not fluctuate a lot when Silence Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Silence Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Silence because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Silence Therapeutics after-hype prediction price

    
  USD 4.53  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.

Prediction based on Rule 16 of the current Silence contract

Based on the Rule 16, the options market is currently suggesting that Silence Therapeutics PLC will have an average daily up or down price movement of about 0.23% per day over the life of the 2025-04-17 option contract. With Silence Therapeutics trading at USD 4.48, that is roughly USD 0.0103 . If you think that the market is fully incorporating Silence Therapeutics' daily price movement you should consider acquiring Silence Therapeutics PLC options at the current volatility level of 3.68%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
  
Check out Silence Therapeutics Basic Forecasting Models to cross-verify your projections.
Intrinsic
Valuation
LowRealHigh
4.0316.7422.12
Details
Naive
Forecast
LowNextHigh
0.083.999.37
Details
6 Analysts
Consensus
LowTargetHigh
48.8653.7059.60
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.46-0.21-0.11
Details

Silence Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of Silence Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Silence Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Silence Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Silence Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting Silence Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Silence Therapeutics' historical news coverage. Silence Therapeutics' after-hype downside and upside margins for the prediction period are 0.23 and 9.91, respectively. We have considered Silence Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
4.48
4.53
After-hype Price
9.91
Upside
Silence Therapeutics is somewhat reliable at this time. Analysis and calculation of next after-hype price of Silence Therapeutics PLC is based on 3 months time horizon.

Silence Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Silence Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Silence Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Silence Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.96 
5.38
  0.05 
  0.19 
9 Events / Month
11 Events / Month
In about 9 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
4.48
4.53
1.12 
10,760  
Notes

Silence Therapeutics Hype Timeline

On the 4th of March Silence Therapeutics PLC is traded for 4.48. The entity has historical hype elasticity of 0.05, and average elasticity to hype of competition of -0.19. Silence is expected to increase in value after the next headline, with the price projected to jump to 4.53 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 1.12%, whereas the daily expected return is at this time at -0.96%. The volatility of related hype on Silence Therapeutics is about 2697.1%, with the expected price after the next announcement by competition of 4.29. The company reported the last year's revenue of 43.26 M. Reported Net Loss for the year was (45.31 M) with profit before taxes, overhead, and interest of 7.27 M. Considering the 90-day investment horizon the next expected press release will be in about 9 days.
Check out Silence Therapeutics Basic Forecasting Models to cross-verify your projections.

Silence Therapeutics Related Hype Analysis

Having access to credible news sources related to Silence Therapeutics' direct competition is more important than ever and may enhance your ability to predict Silence Therapeutics' future price movements. Getting to know how Silence Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Silence Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
CDTXCidara Therapeutics(0.96)9 per month 5.18  0.07  7.77 (8.38) 32.32 
APLTApplied Therapeutics(0.01)6 per month 0.00 (0.29) 8.93 (13.79) 82.78 
CTMXCytomX Therapeutics(0.05)10 per month 0.00 (0.06) 7.32 (7.45) 23.37 
CELLPhenomeX 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
STTKShattuck Labs(0.05)9 per month 6.75  0.08  11.21 (8.40) 50.15 
CCCCC4 Therapeutics 0.02 9 per month 0.00 (0.15) 8.02 (6.60) 22.96 
ELYMELYM Old 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
PRLDPrelude Therapeutics 0.1 6 per month 0.00 (0.02) 12.50 (9.70) 61.66 
GLUEMonte Rosa Therapeutics(0.30)6 per month 0.00 (0.1) 7.68 (8.27) 23.57 
OPTOpthea(0.12)9 per month 3.20  0.16  8.28 (5.63) 20.63 
CNTACentessa Pharmaceuticals PLC 0.14 10 per month 0.00 (0.03) 6.30 (6.19) 15.09 
NUVLNuvalent(2.73)10 per month 0.00 (0.14) 3.34 (5.27) 10.71 
TARSTarsus Pharmaceuticals(0.66)6 per month 0.00 (0.03) 3.94 (5.72) 14.81 
GNFTGenfit 0.03 2 per month 0.00 (0.08) 4.64 (4.44) 13.22 
RNAAvidity Biosciences 0.13 10 per month 0.00 (0.15) 5.36 (5.12) 13.02 
IGMSIGM Biosciences 0.28 8 per month 0.00 (0.20) 8.99 (11.14) 76.54 
CERECerevel Therapeutics Holdings 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
CGEMCullinan Oncology LLC 0.04 8 per month 0.00 (0.19) 4.98 (6.27) 15.27 
MLYSMineralys Therapeutics, Common 0.35 8 per month 0.00 (0.08) 7.79 (6.25) 21.81 

Silence Therapeutics Additional Predictive Modules

Most predictive techniques to examine Silence price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Silence using various technical indicators. When you analyze Silence charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Silence Therapeutics Predictive Indicators

The successful prediction of Silence Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Silence Therapeutics PLC, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Silence Therapeutics based on analysis of Silence Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Silence Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Silence Therapeutics's related companies.
 2022 2023 2024 2025 (projected)
Net Debt To EBITDA1.141.081.922.68
Intangibles To Total Assets0.07750.08660.04790.0455

Story Coverage note for Silence Therapeutics

The number of cover stories for Silence Therapeutics depends on current market conditions and Silence Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Silence Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Silence Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Silence Therapeutics Short Properties

Silence Therapeutics' future price predictability will typically decrease when Silence Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Silence Therapeutics PLC often depends not only on the future outlook of the potential Silence Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Silence Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding138.8 B
Cash And Short Term Investments147.3 M
When determining whether Silence Therapeutics PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Silence Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Silence Therapeutics Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Silence Therapeutics Plc Stock:
Check out Silence Therapeutics Basic Forecasting Models to cross-verify your projections.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.70)
Revenue Per Share
0.368
Quarterly Revenue Growth
(0.59)
Return On Assets
(0.27)
Return On Equity
(1.03)
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.